Details of Protein
| General Information of Protein (ID: PRT00076) | |||||
|---|---|---|---|---|---|
| Name | Interleukin-10 (IL10) | ||||
| Synonyms |
Click to Show/Hide Synonyms of This Protein
IL-10; Cytokine synthesis inhibitory factor; CSIF; Il10; Il-10
|
||||
| Gene Name | Il10 | Gene ID | |||
| UniProt ID | |||||
| Family | Interleukin (IL) | ||||
| Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Function) of This Protein | |||||
| Sequence |
MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQTKDQ
LDNILLTDSLMQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLR MRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS |
||||
| Structure | |||||
| Function | Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators. Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro-inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF-alpha. Interferes also with antigen presentation by reducing the expression of MHC-class II and co-stimulatory molecules, thereby inhibiting their ability to induce T cell activation. In addition, controls the inflammatory response of macrophages by reprogramming essential metabolic pathways including mTOR signaling. | ||||
| Regulatory Network | |||||
| Full List of Metabolite(s) Regulated by This Protein | ||||||
|---|---|---|---|---|---|---|
| Organic acids and derivatives | ||||||
| 2-Hydroxyglutarate | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockout of IL10 | |||||
| Induced Change | 2-Hydroxyglutarate concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Crohn disease [ICD-11: DD70] | |||||
| Details | It is reported that knockout of IL10 leads to the decrease of 2-hydroxyglutarate levels compared with control group. | |||||
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockout of IL10 | |||||
| Induced Change | 2-Hydroxyglutarate concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Crohn disease [ICD-11: DD70] | |||||
| Details | It is reported that knockout of IL10 leads to the decrease of 2-hydroxyglutarate levels compared with control group. | |||||
| Glutaric acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockout of IL10 | |||||
| Induced Change | Glutaric acid concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Crohn disease [ICD-11: DD70] | |||||
| Details | It is reported that knockout of IL10 leads to the decrease of glutaric acid levels compared with control group. | |||||
| Organic oxygen compounds | ||||||
| Fucose | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockout of IL10 | |||||
| Induced Change | Fucose concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Crohn disease [ICD-11: DD70] | |||||
| Details | It is reported that knockout of IL10 leads to the increase of fucose levels compared with control group. | |||||
| Organoheterocyclic compounds | ||||||
| Xanthurenic acid | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockout of IL10 | |||||
| Induced Change | Xanthurenic acid concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Crohn disease [ICD-11: DD70] | |||||
| Details | It is reported that knockout of IL10 leads to the increase of xanthurenic acid levels compared with control group. | |||||
| Full List of Metabolite(s) Regulating This Protein | ||||||
|---|---|---|---|---|---|---|
| Lipids and lipid-like molecules | ||||||
| Resolvin D1 | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[2] | ||||
| Introduced Variation | Resolvin D1 addition (72 hours) | |||||
| Induced Change | IL10 protein expression levels: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Peritonitis [ICD-11: DC50] | |||||
| Details | It is reported that resolvin D1 addition causes the increase of IL10 protein expression compared with control group. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.

